Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO, May 26, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the following upcoming investor conferences:
- Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9, 2016 at 2:30 p.m. ET
- JMP Securities Life Sciences Conference in New York City on Tuesday, June 21, 2016 at 11:30 a.m. ET
Live webcasts of both presentations will be available at http://ir.retrophin.com/events.cfm and archived replays will be accessible for up to 90 days from each presentation date.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Chenodal®, Cholbam® and Thiola®.
Contact: Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
